Non‑Small Cell Lung Cancer | Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer

Featuring perspectives from Drs Alexander Spira and Helena Yu, including the following topics: Introduction  What is an antibody-drug conjugate? (0:00) “HER2-Positive” Non-Small Cell Lung Cancer (NSCLC)  Case: A woman in her mid 50s with HER2 insertion in exon 20 — Dr Yu (8:42) Targeting HER3 in NSCLC  Case: A man in his early 60s with lung cancer with an EGFR mutation — Dr Yu (25:23) TROP2-Directed Treatment  Case: A woman in her early 50s with lung cancer with a KRAS G12V mutation — Dr Spira (36:57) Case: A woman in her mid 60s with metastatic NSCLC and an EGFR exon 19 deletion — Dr Spira (39:32) Novel Agents  Mechanism of action of tusamitamab ravtansine and telisotuzumab vedotin (54:15) CME information and select publications

Om Podcasten

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.